Comparative Pharmacology
Head-to-head clinical analysis: DOXY 100 versus TETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 100 versus TETRACYCLINE HYDROCHLORIDE.
DOXY 100 vs TETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
250-500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 12 hours. Maximum oral dose: 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
6-11 hours (prolonged to 57-120 hours in severe renal impairment; reduced in hepatic dysfunction; clinically relevant for dosing interval adjustments).
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Renal (60% unchanged via glomerular filtration), biliary (40% as active drug and metabolites, with enterohepatic recirculation; fecal elimination of unabsorbed drug).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic